Dopamine receptors and the dopamine hypothesis of schizophrenia

Synapse

Volumn 1, Issue 2, 1987, Pages 133-152

  Seeman, Philip ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Haloperidol; Neuroleptics; Psychosis

Indexed keywords

PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; DOPAMINE; HUMAN; MODELS, NEUROLOGICAL; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SYNAPSES;

EID: 0023254675     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.890010203     Document Type: Article

References (379)

1. Paradoxical reaction to L‐Dopa in schizophrenic patients
2. 2‐dopamine receptor using a novel high affinity radioiodinated probe
3. 2‐dopamine receptor
4. Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system
5. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
6. Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum
7. Ventricular enlargement in schizophrenia: Relationship to positive and negative symptoms
8. Ventricular enlargement in schizophrenia: Definition and prevalence
9. Structural abnormalities in the frontal system in schizophrenia
10. Behavioral effects of L‐Dopa in schizophrenic patients
11. Amphetamine psychosis: Behavioral and biochemical aspects
12. Clinical studies with dopamine‐receptor stimulants
13. Behavioural effects of L‐Dopa in schizophrenic patients
14. Norepinephrine‐dopamine interactions and behaviour
15. 2) receptor
16. Rapid desensitization of presynaptic dopamine autoreceptors during exposure to exogenous dopamine
17. 18F‐labeled butyrophenone neuroleptic drugs in the baboon using position emission tomography
18. Antistereotypic effects of dopamine D‐1 and D‐2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity
19. Behavioural stimulation is induced by separate dopamine D‐1 and D‐2 receptor sites in reserpine‐pretreated but not in normal rats
20. Differential effects of dopamine D‐1 and D‐2 agonists and antagonists in 6‐hydroxydopamine‐lesioned rats
21. Independent dopamine D‐1 and D‐2 receptor regulation of dopamine agonist‐induced hyperactivity in 6‐OHDA lesioned rats; but not in normal rats
22. Differential inhibition by dopamine D‐1 and D‐2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6‐hydroxydopamine lesions
23. 3H]dopamine binds to D‐1 and D‐2 receptors in rat striatum
24. Dopaminergic 3H‐agonist receptors in rat brain: New evidence on localization and pharmacology
25. Antipsychotic drug action in schizophrenic patients: Effect on cortical dopamine metabolism after long‐term treatment
26. Schizophrenia
27. Methylation hypothesis
28. Different effects of D‐1 and D‐2 agonists in rats with unilateral striatal lesions
29. Dopaminergic mechanisms and motor function: Characterization of D‐1 and D‐2 dopamine receptor interactions
30. 3H]acetylcholine in rat striatal slices: An experimental model for drugs that enhance dopaminergic neuro‐transmission
31. 3H]indalpine binding sites in the rat brain: I. Pharmacological characterization
32. Psychotic reactions during tetraethylthiuramdisulfide (Antabuse) therapy
33. Time schedule of apomorphine administration determines the degree of globus pallidus excitation
34. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses
35. Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia
36. Fluorescent antibody studies of immunoglobulin binding by brain tissues
37. Catecholamines and their receptors in blood: Evidence for alterations in schizophrenia
38. Catecholamine—Receptors on blood cells of untreated schizophrenic patients
39. 3H‐spiperone to human lymphocytes: A biological marker in schizophrenia?
40. 2 receptor
41. Site‐specific blockade of dopamine receptors by neuroleptic agents in human brian
42. Antipsychotic drug action: Clinical, biochemical, and pharmacological evidence for site specificity of action
43. Interaction of dopamine receptor ligands with subtypes of the opiate receptor
44. Central dopamine turnover in schizophrenic syndromes
45. Psychoses precipitated by psychotomimetic drugs
46. Brain homovanillic acid: Regional changes over time with antipsychotic drugs
47. SCH 23390 may alter dopamine‐mediated motor behaviour via striatal D‐1 receptors
48. Pharmacological characterization of benzodiazepine receptors in the brain
49. D‐1 dopamine receptor agonist treatment of Parkinson's Disease
50. Evidence that D‐1 dopamine receptors contribute to the supersensitive behavioural responses induced by L‐dihydroxypheny‐lalanine in rats treated neonatally with 6‐hydroxydopamine
51. SCH‐23390 antagonism of a D‐2 dopamine agonist depends upon catecholaminergic neurons
52. Dopamine/neuroleptic receptors in basal hypothalamus and pituitary
53. Postmortem evidence of structural brain changes in schizophrenia
54. Antipsychotic drug effects on the electrical activity of dopaminergic neurons
55. 2 receptors in Huntington's chorea
56. Amphtetamine enhances latent dopaminergic neurotransmission in the rat striatum
57. Dopamine‐sensitive adenylyl cyclase in human caudate nucleus
58. Antipsychotic drugs, neurotransmitters, and schizophrenia
59. Does dopamine have a role in schizophrenia?
60. Effect of chlorpromazine or haloperidol on formation of 3‐methoxytyramine and normetanephrine in mouse brain
61. Sulpiride in tardive dyskinesia
62. 2 dopamine receptors by affinity chromatography
63. 125I‐cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6‐hydroxydopamine or ventral tegmental lesions
64. Dopamine hyperactivity: Effects of neuroleptics alone and in combination with GABA‐agonists
65. Dopamine‐sensitive adenylate cylase in mammalian brain: A possible site of action of antipsychotic drugs
66. Failure of SKF 38393‐A to relieve parkinsonian symptoms induced by 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine in the marmoset
67. 2 receptors
68. Excitation‐mediating and inhibition‐mediating dopamine‐receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data
69. The effect of neuroleptics on the activity of central catecholamine neurones
70. The use of dopamine agonists in the treatment of schizophrenia
71. 2‐receptors and histamine‐sensitive adenylate cyclase: Effects of anti‐psychotics and antidepressants
72. 2 receptors in schizophrenia studied in vivo
73. Selective D‐1 dopamine receptor increase following chronic treatment with SCH23390
74. Dopamine receptors: A classification
75. 3H‐haloperidol
76. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
77. The classification of dopamine receptors: Relationship to radioligand binding
78. Chemical and structural changes in the brain in patients with movement disorder
79. Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder
80. 3H‐flupenthixol binding in post‐mortem brains of schizophrenics: Evidence for a selective increase in dopamine D2 receptors
81. What is wrong with dopaminergic transmission in schizophrenia?
82. Molecular pathology of schizophrenia: More than one disease process?
83. The biology of schizophrenia
84. Two syndromes in schizophrenia?
85. A re‐evaluation of the viral hypothesis: Is psychosis the result of retroviral integration at a site close to the cerebral dominance gene?
86. Dopamine and schizophrenia
87. Dopaminergic mechanisms in schizophrenia: The antipsychotic effect and the disease process
88. Monoamine mechanisms in chronic schizophrenia: Post‐mortem neurochemical findings
89. Abnormal involuntary movements in schizophrenia: Are the related to the disease process or its treatment? Are they associated with changes in dopamine receptors?
90. Changes in D2 dopamine receptor numbers in post‐mortem brain in schizophrenia in relation to the presence of the Type I syndrome and movement disorder
91. A comparison between centrifugation and filtration as a means to separate bound and unbound ligand during 3[H]‐spiroperidol binding
92. Changes in the sensitivity to apomorphine of dopamine receptors modulating dopamine and acetylcholine release after chronic treatment with bromocriptine or haloperidol
93. Research in endorphins and schizophrenia
94. Cholinergic involvement in mental disorders
95. Dopamine inhibits adenylate cyclase in human prolactin‐secreting pituitary adenomas
96. 2 dopamine receptors in calf globus pallidus: Agonist high‐ and low‐affinity sites not regulated by guanine nucleotide
97. Traitement des états d'excitation et d' agitation par une méthode médicamenteuse dérivéé de l'hibernothérapie
98. The third biannual winter workshop on schizophrenia
99. Antipsychotic effect of apomorphine: A retrospective study
100. Dopamine receptor elevation by cholecystokinin
101. 2 receptor interactions
102. Plasma proteins in schizophrenia: A review
103. Striatal muscarinic receptors: Regulation by dopaminergic agonists
104. 2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary
105. Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency
106. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography
107. 2 dopamine receptor binding in the living human brain by PET
108. Clinical effects of apomorphine in schizophrenia
109. Hormonal effects of apomorphine in schizophrenia
110. Are dopamine receptors present on human lymphocytes?
111. Changes in apomorphine‐induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D‐2 receptors, but not with increases in D‐1 receptors
112. SKF 38393 and apomorphine modify locomotion and exploration in rats placed on a holeboard by separate actions at dopamine D‐1 and D‐2 receptors
113. A gas chromatographic method for determining haloperidol
114. Biogenic amines and schizophrenia
115. Restitutive processes in the regulation of behaviour
116. 2 ‐receptor
117. Dopamine receptors: Pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum
118. The functional state of the dopamine receptor in the anterior pituitary is in the high‐affinity form
119. 2 receptors in the anterior pituitary: A single population without reciprocal agonist/antagonist states
120. 2 receptors in brain and anterior pituitary recognize agonist and antagonist actions of (−)‐3PPP
121. Effect of CB 154 (2‐bromo‐alpha‐ergocryptine) on paralysis agitans compared with Madopar in a double‐blind, crossover trial
122. Sulpiride in tardive dyskinesia
123. The effect of L‐Dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. A double‐blind cross‐over trial with Madopar and placebo
124. Behavioural correlations of dopamine receptor activation
125. Stimulation of dopamine release by GABA in rat striatal slices
126. The acetylcholine receptor
127. Dopamine agonist induced self‐mutilative biting behaviour in monkeys with unilateral ventromedial tegmental lesions of the brainstem: Possible pharmacological model for Lesch‐Nyhan syndrome
128. Behavioural effects of L‐DOPA in man
129. Calcium channel blockade: Possible explanation for thioridazine's peripheral side effects
130. Modulation of striatal dopaminergic function by local injection of 5′‐N‐ethylcarboxamide adenosine
131. The dopamine/neuroleptic receptor
132. 2 dopamine receptors from the high‐ to the low‐affinity state for dopamine agonsits, using sodium ions and guanine nucleotide
133. 3H‐Domperidone labels only a single population of receptors which convert from high to low affinity for dopamine in rat brain
134. 2 receptor density increased markedly, using constant infusion of haloperidol by osmotic pump
135. Sulpiride in tardive dyskinesia
136. Effects of sulpiride on persistent neuroleptic‐induced dyskinesia in monkeys
137. Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness
138. 3H‐dopamine binding to rat striatal D‐2 and D‐3 sites: Enhancement by magnesium and inhibition by guanine nucleotides and sodium
139. Interactions of agonists with D‐2 dopamine receptors: Evidence for a single receptor population existing in multiple agonist affinity‐states in rat striatal membranes
140. Remarques sur l'action du 4560 R.P. sur l'agitation maniaque
141. Schizophrenia: Biochemical and physiologic aberrations
142. 3H)5‐hydroxytryptamine in slices of rat occipital cortex
143. Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites
144. Effect of the dopamine D‐1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6‐hydroxy‐dopamine denervated rats
145. 1 dopamine receptors in rat striatum
146. Differential effects of bromocriptine on dopamine and acetylcholine release modulatory receptors
147. Apomorphine in schizophrenia
148. The effects of ceruletide in schizophrenia
149. Parkinson's disease: From brain homogenate to treatment
150. Brain catecholamines in schizophrenia—a good case for noradrenaline
151. Three cases of schizophrenia treated with L‐Dopa
152. Effect of L‐Dopa in schizophrenia
153. Double‐blind controlled study of L‐Dopa therapy in schizophrenia
154. Double‐blind controlled study of L‐Dopa therapy in schizophrenia
155. The electrical properties of isolated human prolactin‐secreting adenoma cells and their modification by dopamine
156. Pathophysiology of schizophrenia—causal role for dopamine or noradrenaline?
157. Mechanisms of action of LSD
158. Hypothesis: Bromocriptine lacks intrinsic dopamine receptor stimulating properties
159. Frequency‐dependent muscarinic receptor modulation of acetylcholine and dopamine release from rabbit striatum
160. Methylphenidate, dextroam‐phetamine, and levamfetamine: Effects on schizophrenic symptoms
161. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate
162. 3H]GBR‐12935 binding in brain: A radioligand for selective labelling of the dopamine transport complex
163. The distribution of the butyrophenones haloperidol, trifluperidol, moperone, and clofuperol in rats, and its relationship with their neuroleptic activity
164. Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity
165. 3H] doxepin
166. Multiple receptors for dopamine
167. Dopaminesensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “Dopamine Receptor.”
168. Pharmacological and biochemical evidence for the existence of two categories of dopamine receptor
169. Brain contribution to the haloperidol‐induced increase in plasma homovanillic acid
170. An independent analysis of the Copenhagen sample of the Danish adoption study of schizophrenia
171. Biochemical theories of schizophrenia
172. Biochemistry and mental function
173. Mental illness in the biological and adoptive relatives of schizophrenic adaptees: Findings relevant to genetic and environmental factors in etiology
174. Postmortem neurochemical studies in chronic schizophrenia
175. Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine
176. Specific effect of haloperidol on dopamine turnover in the fronal cortex
177. Is the low incidence of extrapyramidal side‐effects of antipsychotics associated with antimuscarinic properties?
178. 3H]3‐(3‐hydroxyphenyl)‐N‐(1‐propyl)piperidine
179. 3H‐domperidone binding and its displacement by dopamine in rat striatal homogenates
180. Dopamine receptors in normal and schizophrenic human brains
181. Elevation of brain neuroleptic/dopamine receptors in schizophrenia
182. 3H‐apomorphine in schizophrenic brains
183. 3 binding sites in rat striatum
184. 3H‐antagonists
185. 3H] spiroperidol binding on lymphocytes: Changes in two different groups of schizophrenic patients and effect of neuroleptic treatment
186. Beta‐endorphin and naloxone in psychiatric patients: Clinical and biological effects
187. Dopamine autoreceptors differ pharmacologically from postsynaptic dopamine receptors: Effects of (−)‐N‐(2‐chlorethyl)‐norapomorphine
188. The pharmacological distinction between central pre‐ and postsynaptic dopamine receptors: Implications for the pathology and therapy of schizophrenia
189. The striatal cholinergic interneuron: Synaptic target of dopaminergic terminals?
190. 3H] acetylcholine release in slices of cat caudate
191. Apomorphine and schizophrenia
192. 2 dopamine receptors
193. 3H‐ligand for serotonin receptor binding sites
194. Endorphins in human cerebrospinal fluid: Clinical correlations to some psychotic states
195. 3 dopaminergic sites in human, rat and calf brain
196. 3H‐spiperone binding to rat brain regions
197. 3 sites) kin human and rat brain
198. Lateral ventricular size, psychopathology, and medication response in the psychoses
199. Dopamine receptors and schizophrenia: Drug effect or illness?
200. 3H‐spiperone binding in normal and schizophrenic postmortem human brain
201. Increased brain dopamine and dopamine receptors in schizophrenia
202. Chronic neuroleptic treatment increases D‐2 but not D‐1 receptors in rat striatum
203. 2 receptors are not affected by 6‐hydroxydopamine or chronic haloperidol treatment
204. 3H]diazepam to rat brain homogenates
205. 2 dopamine receptors
206. Solubilization of dopamine receptors from human and dog brain
207. 2) on human lymphocutes?
208. Absence of dopamine and muscarinic receptors on human lymphocytes
209. Neurochemical effects of some ergot derivatives: A basis for their antiparkinson actions
210. Dopamine receptor profile of co‐dergocrine (Hydergine) and its components
211. 3H]‐N‐allylnormetazocine bind to different sites in mouse brain
212. Antipsychotic drug actions: A clue to the neuropathology of schizophrenia?
213. Dopamine and the pharmacology of schizophrenia: The state of the evidence
214. Estimating the genetic contribution to schizophrenia
215. Neurotransmitter theories of schizophrenia
216. 2 dopamine receptors
217. Possible changes in striatal and limbic cholinergic systems in schizophrenia
218. Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro
219. 1 antagonist
220. 1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics
221. Relevance of dopamine autoreceptors for psychiatry: Preclinical and clinical studies
222. The dopamine hypothesis of schizophrenia: A review
223. Perceptual capacity, functions of the corpus striatum and schizophrenia
224. The dopamine receptor in the intermediate lobe of the rat pituitary gland is negatively coupled to adenylate cyclase
225. 1 antagonist SCH 23390
226. Catalepsy induced by SCH 23390 in rats
227. Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia
228. Increased specific neuroleptic binding after chronic haloperidol in rats
229. Brain neurotransmitter receptors after long‐term haloperodol: Dopamine, acetylcholine, serotonin, alpha‐adrenergic and naloxone receptors
230. The dopamine receptor in the intermediate lobe of the rat pituitary gland: Pharmacological characterization
231. Control of erythrocyte shape by calmodulin
232. 125I‐labelled analogue
233. Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine
234. 3H‐YM‐09151–2
235. 2 receptors photolabeled by iodoazido‐clebopride
236. 3H]SCH 23390. Solubilization of a guanine nucleotide‐sensitive form of the receptor
237. 1 receptor: Partial purification of a digitonin‐solubilized receptor‐guanine nucleotide binding complex
238. 3H] azidomethylspiperone
239. 1 agonist SKF 38393, reverses parkinsonism induced by 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP) in the common marmoset
240. 14 in rat brain after chlorpromazine
241. Muscarinic receptors modulate dopamine‐activated adenylate cyclase of rat striatum
242. 1 dopamine receptor blocker, enhances the firing rate of nigral dopaminergic neurons but fails to activate striatal tyrosine hydroxylase
243. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum
244. Increased dopamine‐receptor sensitivity in schizophrenia
245. Effects of dopamine on cyclic AMP concentration in the anterior pituitary gland in vitro
246. 3H]spiroperidol
247. Interactions of neuroleptic compounds at alpha‐adrenergic receptor affinity states in bovine caudate nucleus
248. Gamma‐aminubutyric‐acid deficiency in brain of schizophrenic patients
249. Short‐term naloxone administration in schizophrenic and manic patients
250. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients
251. 1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease
252. SCH23390 blocks D‐1 and D‐2 dopamine receptors in rat neostriatum in vitro
253. The effects of SCH23390, YM 09151–2, (+)‐ and (−)‐3‐PPP and some classical neuroleptics on D‐1 and D‐2 receptors in rat neostriatum in vitro
254. The pathogenesis of schizophrenia
255. 3H]SCH23390 binding sites increase after chronic blockade of D‐1 dopamine receptors
256. Cerebrospinal fluid amine metabolites in acute schizophrenia
257. Peptides in the cerebrospinal fluid of neuropsychiatric patients: An approach to central nervous system peptide function
258. Time‐dependent effects of phenothiazines on dopamine turnover in psychiatric patients
259. Purification of bovine dopamine D‐2 receptor by affinity chromatography
260. A clinical and pharmacodynamic evaluation of sulpiride
261. 3H]azidosulpride
262. 3H]desipramine to rat brain: A presynaptic marker for noradrenergic uptake sites
263. Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue
264. Ventricular enlargement in schizophrenia. The validity of computerised tomographic findings
265. Amygdala dopamine asymmetry in schizophrenia: Neurochemical evidence for a left temporal lobe dysfunction
266. Thioridazine is not specific for limbic dopamine receptors
267. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro
268. The pharmacological basis of the therapeutic activity of clebopride and related substituted benzamides
269. Correlation between neuroleptic‐induced suppression of stereotyped behaviour and HVA concentrations in rat brain
270. 1 stimulation
271. Dopamine receptor alteration in schizophrenia: Neurondocrine evidence
272. 3H‐spiroperidol binding in schizophrenia: Preliminary findings
273. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats
274. Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs
275. D‐1 and D‐2 dopamine receptor blockade: Interactive effects in vitro and in vivo
276. Differential regional development of tolerance to increase in dopamine turnover upon repeated neurleptic administration
277. Differential changes in DOPAC levels in the hippocampal formation, septum and striatum of the rat induced by acute and repeated neuroleptic treatment
278. Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: Evidence against dopamine receptor multiplicity
279. 1 dopamine receptors in dopaminergic control of striatal cholinergic transmission
280. 3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease
281. Inhibition of dopamine‐stimulated cyclic AMP efflux from rat neostriatal slices by activation of mu‐and delta‐opioid receptors: A permissive role for D‐2 dopamine receptors
282. 3H]Threo‐(±)‐methylphenidate binding to 3,4‐dihydroxyphenylethylamine uptake sites in corpus striatum: Correlation with the stimulant properties of ritalinic acid esters
283. Membrane stabilization by drugs: Tranquilizers, steroids and anesthetics
284. The membrane actions of anesthetics and tranquilizers
285. Anti‐schizophrenic drugs—membrane receptor sites of action
286. Brain dopamine receptors
287. Dopamine receptors in post‐mortem schizophrenic brains
288. Nomenclature of central and peripheral dopaminergic sites and receptors
289. Dopamine/neuroleptic receptors in schizophrenia
290. The surface activity of tranquilizers
291. 3H‐labeled antagonist
292. The dopamine‐releasing actions of neuroleptics and ethanol
293. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurones
294. Dopamine receptors in the schizophrenic brain
295. 3H]‐azido‐methylspiperone
296. Neuroleptics have identical potencies in human brain limbic and putamen regions
297. Erythrocyte membrane stabilization by tranquilizers and anti‐histamines
298. Dopamine receptor‐block and nigral fiber impulse blockade by major tranquilizers
299. The nerve impulse‐blocking actions of tranquilizers, and the binding of neuroleptics to synaptosome membranes
300. Tranquilizer receptors in rat striatum
301. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays
302. Antipsychotic drug doses and neuroleptic/dopamine receptors
303. Elevation of brain neuroleptic/dopamine receptors in schizophrenia
304. Serotonin receptors in hippocampus and frontal cortex
305. Bimodal distribution of dopamine receptor densities in brains of schizophrenics
306. 3H‐spiperone depend on tissue concentration: Analysis and examples
307. 1 receptors from high to low affinity for dopamine
308. 2 receptor binding sites for agonists: A tetrahedral model
309. Functional states of dopamine receptors
310. 2 receptors
311. 1 receptor
312. 2‐dopamine receptor
313. Anterior pituitary dopamine receptors: Demonstration and interconvertible high and low affinity states of the D‐2 dopamine receptor
314. Molecular mechanisms of receptor desensitization using the beta‐adrenergic receptor‐coupled adenylate cyclase system as a model
315. The effects of acute and chronic haloperidol treatment on spontaneously firing neurons in the caudate nucleus of the rat
316. Effect of apomorphine on schizophrenic symptoms
317. Recent progress in schizophrenia research
318. Amphetamine psychosis: A “model” schizophrenia mediated by catecholamines
319. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor
320. 3H‐domperidone binding sites differ in rat striatum and pituitary
321. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system
322. Further functional in vitro comparison of pre‐ and postsynaptic dopamine receptors in the rabbit caudate nucleus
323. Impaired presynaptic regulation of norepinephrine in schizophrenia
324. An anatomy of schizophrenia?
325. Opposing roles for D‐1 and D‐2 dopamine receptors in efflux of cyclic AMP from rat neostriatum
326. +‐stimulated release of acetylcholine from rat neostriatum
327. In vitro acetylcholine release from rat caudate nucleus as a new model for testing drugs with dopamine‐receptor activity
328. 2‐dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma‐aminobutyric acid, glutamate or serotonin
329. Opposing roles for D‐1 and D‐2 dopamine receptors in regulating the excitability of growth hormone‐producing cells in the snail lymnaea stagnalis
330. 3H]haloperidol binding in guinea pig brain membranes
331. Neuronal cholecystokinin and schizophrenia: Pathogenic and therapeutic studies
332. The pathophysiologic basis of tardive dyskinesia
333. Increased CSF levels of endorphines in chronic psychosis
334. 3) in rat brain
335. High‐affinity binding of agonists to beta‐adrenergic receptors on intact cells
336. The viral hypothesis of schizophrenia
337. Increased dopamine metabolism in the putamen and caudate in schizophrenic patients
338. 3H]mepyramine
339. Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors
340. 3H]2‐amino‐6, 7‐dihydroxy‐1, 2, 3, 4‐tetrahydronapthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively
341. 3H]spiroperidol
342. Impaired noradrenergic transmission in schizophrenia?
343. Dopamine‐beta‐hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy
344. Neuroleptic‐like profile of gamma‐type endorphins as related to schizophrenia
345. The significance of dopamine‐receptor blockade for the mechanism of action of neuroleptic drugs
346. Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice
347. The behavioural pharmacology of butaclamol hydrochloride (AY‐23,028), a new potent neurleptic drug
348. Antithymic antibodies in schizophrenic sera
349. Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics
350. 2 dopamine receptors by magnesium and sodium ions
351. Dependence of dopamine receptor conversion from agonist high‐ to low‐affinity state on temperature and sodium ions
352. Endorphins, dopamine, and schizophrenia
353. Murine lymphocytes lack clearly defined receptors for muscarinic and dopaminergic ligands
354. Neuropathological studies of schizophrenia: A selective review
355. 3H]lysergic acid diethylamide in calf caudate
356. 3H‐LSD
357. Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat
358. Interaction between cholecystokinin and central dopamine pathways. A negative report
359. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain
360. Dopamine receptor binding of C‐11‐3‐N‐methylspiperone in the caudate in schizophrenia and bipolar disorder: A preliminary report
361. Quantification of neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity
362. 2 dopamine receptors in drug‐naive schizophrenics
363. 2‐dopamine receptor of the anterior pituitary gland
364. 2 dopamine receptor in calf brain: Partial conversion by guanine nucleotide
365. The action of L‐DOPA on schizophrenic patients
366. Action of L‐Dopa in drug induced extrapyramidalism
367. A gas chromatographic method for the determination of haloperidol in human plasma